Icon Plc $ICLR Position Trimmed by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS trimmed its holdings in shares of Icon Plc (NASDAQ:ICLR) by 53.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 25,037 shares of the medical research company’s stock after selling 29,100 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in Icon were worth $4,562,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. WINTON GROUP Ltd bought a new stake in shares of Icon during the 2nd quarter worth $254,000. Daiwa Securities Group Inc. boosted its stake in shares of Icon by 19.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company’s stock worth $4,094,000 after acquiring an additional 4,546 shares in the last quarter. Frontier Capital Management Co. LLC boosted its stake in shares of Icon by 97.6% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company’s stock worth $10,379,000 after acquiring an additional 35,253 shares in the last quarter. Peapack Gladstone Financial Corp bought a new stake in shares of Icon during the 2nd quarter worth $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Icon by 58.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock worth $113,000 after acquiring an additional 289 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors.

Icon Trading Down 4.6%

Icon stock opened at $112.85 on Friday. The company has a 50 day moving average price of $107.01 and a 200 day moving average price of $148.97. Icon Plc has a 52 week low of $66.57 and a 52 week high of $211.00. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. The firm has a market capitalization of $9.11 billion, a price-to-earnings ratio of 15.27, a P/E/G ratio of 2.86 and a beta of 1.23.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ICLR. Truist Financial reissued a “hold” rating and set a $222.00 price objective (down from $231.00) on shares of Icon in a research note on Thursday, January 8th. TD Cowen raised Icon from a “hold” rating to a “buy” rating and reduced their price objective for the stock from $183.00 to $120.00 in a research note on Wednesday, February 18th. Mizuho set a $216.00 price objective on Icon in a research note on Friday, January 9th. Robert W. Baird set a $119.00 price objective on Icon in a research note on Friday, February 13th. Finally, Jefferies Financial Group set a $135.00 price objective on Icon and gave the stock a “buy” rating in a research note on Monday, February 23rd. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, Icon has an average rating of “Hold” and an average target price of $147.85.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.